Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3762
- Registration Number
- NCT01225874
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
- Conditions
- Ann Arbor Stage I B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaAdult B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Down SyndromeHypodiploid B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveAnn Arbor Stage II B Lymphoblastic LymphomaChildhood B Lymphoblastic Lymphoma
- Interventions
- Drug: DexamethasoneDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: MethotrexateDrug: Doxorubicin HydrochlorideOther: Quality-of-Life AssessmentOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationDrug: Leucovorin CalciumDrug: Vincristine SulfateDrug: PegaspargaseDrug: Thioguanine
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 9350
- Registration Number
- NCT01190930
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 6
- Registration Number
- NCT01186328
- Locations
- 🇦🇺
Sydney Children's Hospital, Sydney, Australia
🇺🇸St. Jude, Memphis, Tennessee, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: rituximabBiological: paliferminDrug: cyclophosphamideProcedure: allogeneic hematopoietic stem cell transplantationDrug: cytarabineDrug: daunorubicin hydrochlorideRadiation: total-body irradiationDrug: etoposideDrug: fludarabine phosphateDrug: imatinib mesylateDrug: melphalanDrug: mercaptopurineDrug: methotrexateDrug: nelarabineDrug: pegaspargaseDrug: vincristine sulfate
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1033
- Registration Number
- NCT01085617
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 180
- Registration Number
- NCT01005758
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01005914
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Treatment of Older Adults With Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00973752
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 470
- Registration Number
- NCT00967057
- Locations
- 🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇦🇺Women's and Children's Hospital, North Adelaide, South Australia, Australia
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Emory University
- Registration Number
- NCT00957320
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT00890656
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.